https://www.thebodypro.com/category/triumeq-pro/tag/conference-coverage

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Triumeq Virologically Superior to Boosted-Atazanavir Regimen in Women's Trial Img

Triumeq Virologically Superior to Boosted-Atazanavir Regimen in Women's Trial

A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.

Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment Img

Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single-tablet regimen of Triumeq.

Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load Img

Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load

Paul Sax, M.D., recaps an important study presented at ICAAC 2015, which highlighted 24-week results for patients switching to abacavir/dolutegravir/lamivudine (Triumeq).